140 related articles for article (PubMed ID: 9740080)
1. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma.
Talvensaari-Mattila A; Pääkkö P; Höyhtyä M; Blanco-Sequeiros G; Turpeenniemi-Hujanen T
Cancer; 1998 Sep; 83(6):1153-62. PubMed ID: 9740080
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy.
Talvensaari-Mattila A; Pääkko P; Blanco-Sequeiros G; Turpeenniemi-Hujanen T
Breast Cancer Res Treat; 2001 Jan; 65(1):55-61. PubMed ID: 11245340
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
4. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma.
Hirvonen R; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Breast Cancer Res Treat; 2003 Jan; 77(1):85-91. PubMed ID: 12602907
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma.
Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Br J Cancer; 2003 Oct; 89(7):1270-5. PubMed ID: 14520459
[TBL] [Abstract][Full Text] [Related]
7. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
Remacle AG; Noël A; Duggan C; McDermott E; O'Higgins N; Foidart JM; Duffy MJ
Br J Cancer; 1998 Mar; 77(6):926-31. PubMed ID: 9528836
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.
Li HC; Cao DC; Liu Y; Hou YF; Wu J; Lu JS; Di GH; Liu G; Li FM; Ou ZL; Jie C; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2004 Nov; 88(1):75-85. PubMed ID: 15538048
[TBL] [Abstract][Full Text] [Related]
9. pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival.
Thor AD; Koerner FC; Edgerton SM; Wood WC; Stracher MA; Schwartz LH
Breast Cancer Res Treat; 1992; 21(2):111-9. PubMed ID: 1627814
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Clin Cancer Res; 2004 May; 10(9):3110-6. PubMed ID: 15131051
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients.
Puzovic V; Brcic I; Ranogajec I; Jakic-Razumovic J
Neoplasma; 2014; 61(4):439-46. PubMed ID: 24645837
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].
Zhang B; Liu YX; Cao WF; Cao XC; Ning LS; Hao XS
Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):471-6. PubMed ID: 19035119
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
Allgayer H; Babic R; Beyer BC; Grützner KU; Tarabichi A; Schildberg FW; Heiss MM
Oncology; 1998; 55(2):152-60. PubMed ID: 9499190
[TBL] [Abstract][Full Text] [Related]
17. Worse prognosis in breast cancer patients can be predicted by immunohistochemical analysis of positive MMP-2 and negative estrogen and progesterone receptors.
Ramos EA; Silva CT; Manica GC; Pereira IT; Klassen LM; Ribeiro EM; Cavalli IJ; Braun-Prado K; Lima RS; Urban CA; Costa FF; Noronha L; Klassen G
Rev Assoc Med Bras (1992); 2016 Nov; 62(8):774-781. PubMed ID: 27992019
[TBL] [Abstract][Full Text] [Related]
18. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA
Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503
[TBL] [Abstract][Full Text] [Related]
19. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
20. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations.
Niemiec J; Adamczyk A; Małecki K; Ambicka A; Ryś J
Clin Breast Cancer; 2013 Apr; 13(2):119-28. PubMed ID: 23375518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
